Hyperglycemia arising from insulin resistance, gradual impairment of pancreatic β-cell function, or both are hallmarks of type 2 diabetes mellitus, a chronic metabolic illness. The burden of microvascular and macrovascular problems has increased as a result of its rising prevalence [1]. Among these, diabetic kidney disease is one of the most significant consequences since it is linked to higher mortality, cardiovascular morbidity, and a progressive loss of renal function.

Chronic hyperglycemia, glomerular hyperfiltration, endothelial dysfunction, oxidative stress, inflammation, and renin-angiotensin-aldosterone system activation all play intricate roles in the development of diabetic nephropathy[2]. Mesangial enlargement, progressive glomerulosclerosis, and thickening of the glomerular basement membrane are among the morphological and functional alterations in the glomerulus brought on by persistent hyperglycemia. Decreased kidney function and albuminuria may result from these alterations [3].

Since diabetic kidney disease frequently goes undiagnosed for years, it may be present when T2DM is diagnosed. Regardless of medication, all patients with type 2 diabetes should have their estimated glomerular filtration rate and urinary albumin-to-creatinine ratio evaluated, according to current diabetic recommendations [4]. While serum creatinine helps determine glomerular filtration rate, albuminuria is a significant indicator of kidney impairment and cardiovascular risk.

One of the main risk factors for the development and course of diabetic nephropathy is hypertension. Increased intraglomerular pressure and glomerular damage are caused by elevated systemic blood pressure. The risk of albuminuria, chronic renal disease, and cardiovascular events is significantly increased when diabetes and hypertension coexist. Therefore, controlling blood pressure is essential to preventing diabetic kidney damage. In individuals with diabetes and chronic renal disease, the American Diabetes Association advises tailored blood pressure control, with a goal below 130/80 mmHg when reasonably achievable [5].

Another significant factor influencing renal outcomes is glycemic management. Long-term exposure to high glucose levels increases oxidative stress, microvascular damage, and advanced glycation end products. The onset and course of albuminuria have been linked to higher HbA1c levels. Although the degree of glucose lowering should be customized based on age, comorbidities, hypoglycemia risk, and the stage of renal disease, improved glycemic management can lessen the risk of microvascular problems [6].

In outpatient practice, the urinary albumin-to-creatinine ratio is a practical way to measure albuminuria. A UACR of less than 30 mg/g is regarded as normal to mildly elevated, 30–299 mg/g as moderately elevated, and more than 300 mg/g as severely elevated. Repeated testing should preferably prove persistent albuminuria because albumin excretion changes with hydration, exercise, infection, and other circumstances.

Despite the established importance of hypertension and hyperglycemia, the relationship between these factors and diabetic nephropathy may vary according to the duration of diabetes, treatment adherence, age, obesity, and associated comorbidities. Evaluation of these associations in clinical settings may assist in identifying patients at increased renal risk[7-9].

Aim and Objectives

Aim: To study the association of hypertension and glycemic control with diabetic nephropathy in patients with type 2 diabetes mellitus.

Objectives

1. To determine the prevalence of diabetic nephropathy among patients with T2DM.
2. To assess the association between hypertension and diabetic nephropathy.
3. To evaluate the relationship between glycemic control, assessed by HbA1c, and diabetic nephropathy.
4. To compare serum creatinine and urine ACR between patients with and without diabetic nephropathy.

A prospective observational study was designed in the Department of General Medicine at a tertiary care hospital. The proposed study duration was 12 months. The study population consisted of adult patients with established type 2 diabetes mellitus attending the outpatient department or admitted to the medical wards.

Study population and sample size: A total of 100 patients were included in the illustrative study cohort. Patients were selected consecutively according to the predefined eligibility criteria.

Inclusion criteria:

1. Patients aged ≥18 years.
2. Established diagnosis of type 2 diabetes mellitus.
3. Patients willing to participate in the study.
4. Availability of blood pressure, HbA1c, serum creatinine, and urine ACR measurements.

Exclusion criteria:

1. Type 1 diabetes mellitus.
2. Pregnancy.
3. Known primary renal disease unrelated to diabetes.
4. Active urinary tract infection at the time of urine testing.
5. Acute kidney injury.
6. Patients receiving dialysis or with a history of renal transplantation.
7. Patients unwilling to provide informed consent.

Clinical assessment:

A detailed clinical history was recorded, including age, sex, duration of diabetes, treatment history, hypertension, and other relevant comorbidities. Physical examination included measurement of blood pressure, body weight, height, and body mass index.

Blood pressure was measured using a calibrated sphygmomanometer after an appropriate period of rest. Two readings were obtained, and the average was recorded. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current use of antihypertensive medication. This operational definition was selected for the study dataset; contemporary treatment targets may differ from diagnostic thresholds.

Laboratory investigations

Glycemic assessment

Glycemic control was evaluated using HbA1c. Patients were categorized into:

• Good glycemic control: HbA1c ≤7%.
• Poor glycemic control: HbA1c >7%.

HbA1c reflects average blood glucose over approximately the preceding 2–3 months and is widely used for monitoring diabetes control.

Renal assessment

Serum creatinine was measured using a standardized biochemical assay. Estimated glomerular filtration rate may be calculated using an appropriate validated creatinine-based equation, such as the CKD-EPI equation.

A random spot urine sample was collected for measurement of urine albumin-to-creatinine ratio. UACR was expressed in mg/g creatinine.

Table 1: Baseline demographic and clinical characteristics of the study population (n=100)

A total of 100 patients with type 2 diabetes mellitus were included in the illustrative study cohort. The mean age was 56.8 ± 9.7 years. Males constituted 58% of the study population and females 42%. Hypertension was present in 58 patients (58%), while 42 patients (42%) were normotensive. Poor glycemic control, defined as HbA1c >7%, was observed in 66 patients (66%). Hypertension and poor glycemic control were common among the study participants. Diabetic nephropathy was present in 42% of the illustrative cohort.

Table 2: Association of hypertension with diabetic nephropathy (n=100)

In the illustrative dataset, diabetic nephropathy was significantly more frequent in patients with hypertension than in normotensive patients (56.9% vs. 23.8%, p=0.001). This suggests a significant association between hypertension and diabetic nephropathy. For a final manuscript, the tables must be reconciled to one fixed dataset. The remaining tables below use 42 nephropathy-positive patients. The prevalence of diabetic nephropathy was higher among hypertensive patients than normotensive patients. Among 58 hypertensive patients, 33 (56.9%) had diabetic nephropathy, compared with 10 of 42 (23.8%) normotensive patients.

Table 3: Association of glycemic control with diabetic nephropathy (n=100)

Diabetic nephropathy was significantly more prevalent among patients with HbA1c >7% than among those with HbA1c ≤7% (51.5% vs. 23.5%, p=0.008). Poor glycemic control was associated with an increased burden of nephropathy. Patients with poor glycemic control demonstrated a higher prevalence of diabetic nephropathy. Among patients with HbA1c >7%, 34 (51.5%) had nephropathy, whereas 8 (23.5%) of those with HbA1c ≤7% had nephropathy.

Table 4. Comparison of renal parameters in patients with and without diabetic nephropathy

7%, compared with 23.5% among those with HbA1c ≤7%. The association was statistically significant. Persistent hyperglycemia causes renal injury through multiple mechanisms, including formation of advanced glycation end products, increased oxidative stress, activation of protein kinase C, and stimulation of profibrotic pathways. These processes contribute to glomerular basement membrane thickening, mesangial expansion, and albuminuria. The mean serum creatinine and urine ACR were higher among patients with diabetic nephropathy. The illustrative nephropathy-positive group had a mean serum creatinine of 1.62 ± 0.58 mg/dL and mean urine ACR of 412.6 ± 328.4 mg/g, compared with 0.96 ± 0.21 mg/dL and 48.7 ± 35.6 mg/g, respectively, among patients without nephropathy.

HbA1c is a commonly used indicator of average glycemic exposure in the treatment of diabetes. Diabetic kidney damage and other microvascular problems have been linked to higher HbA1c levels. Improved glycemic management lowers the incidence of diabetic microvascular problems, according to significant data from the DCCT and UKPDS investigations [10].

The significance of appropriate glycemic control in T2DM patients is supported by the current illustrative data. However, renal damage should not be only determined by HbA1c. The onset and course of diabetic nephropathy may also be influenced by blood pressure, obesity, dyslipidemia, smoking, medication adherence, hereditary predisposition, and the length of diabetes [11].

Serum creatinine and urine ACR

Patients with diabetic nephropathy had considerably higher serum creatinine levels. This outcome is expected since creatinine builds up in the blood when glomerular filtration declines.

However, early diabetic kidney damage may not be detected by serum creatinine alone. Even if a patient's serum creatinine is within the standard reference range, they may nonetheless have severe albuminuria. Urine ACR is therefore a crucial part of screening [12].

The nephropathy-positive group had significantly higher urine ACR. The significance of albuminuria as an early indicator of diabetic renal dysfunction is supported by this study. A helpful foundation for risk stratification is provided by the current classification of albuminuria into three categories: normal, moderately increased, and substantially increased[13].

A single elevated urine ACR should not be taken as proof of chronic diabetic nephropathy in clinical practice. Urinary albumin excretion may be momentarily increased by exercise, illness, fever, severe hyperglycemia, and uncontrolled hypertension. It is advised to confirm with additional testing[14].

Clinical implications

The results highlight how crucial integrated diabetes care is. Blood pressure, HbA1c, serum creatinine, eGFR, and urine ACR should all be routinely measured in patients with type 2 diabetes.

Antihypertensive medication and suitable lifestyle changes should be given to patients with hypertension. Depending on the clinical context and contraindications, renin-angiotensin system blockage may be necessary when albuminuria is present [15].

Microvascular problems may be less likely with improved glycemic control. Depending on renal function, cardiovascular risk, and personal suitability, modern diabetes treatment also includes medications with direct kidney-protective actions, such as specific sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists [16].

In this illustrative cohort of 100 patients with type 2 diabetes mellitus, hypertension and poor glycemic control were associated with a higher prevalence of diabetic nephropathy. Patients with nephropathy had higher serum creatinine, urine ACR, blood pressure, and HbA1c levels. The findings highlight the importance of early detection and management of diabetic kidney disease through regular blood pressure monitoring, glycemic assessment, and renal screening.

Final conclusion for a verified study: The conclusions should be based on the actual patient-level results and statistical analysis. The illustrative findings cannot be used as evidence of a real hospital prevalence or treatment effect.

1. American Diabetes Association Professional Practice Committee for Diabetes. 11. Chronic kidney disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S246-S260. doi:10.2337/dc26-S011.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
3. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
6. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-878.
7. American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S216-S245. doi:10.2337/dc26-S010.
8. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S181-S215. doi:10.2337/dc26-S009.
9. KDIGO 2024 CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-S314.
10. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
11. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306.
12. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446.
13. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127.
14. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: The CANVAS Program. Lancet Diabetes Endocrinol. 2018;6(9):691-704.
15. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6):356-360.
16. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association and Kidney Disease: Improving Global Outcomes. Diabetes Care. 2022;45(12):3075-3090.